Thirty-two-week results from TALON, a Phase IIIb study of brolucizumab versus aflibercept in a matched (Treat-and-Extend) regimen in patients with neovascular age-related macular degeneration
Author: Peter J. Kertes
Co-authors: Carl Regillo, Peter K. Kaiser, Ramin Tadayoni, Mark Gillies, Iryna Lobach, Siegbert Guenther, Tina Maio-Twofoot, Dsouza D, Frank G. Holz